Cargando…

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment

Mirogabalin (DS‐5565) is a novel preferentially selective α(2)δ‐1 ligand being developed for the treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia. The current multicenter open‐label study determined the effect of varying degrees of renal impairment on the pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Manabu, Tajima, Naoyuki, Shimizu, Takako, Sugihara, Masahiro, Furihata, Kenichi, Harada, Kazuhiro, Ishizuka, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Special Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763271/ https://www.ncbi.nlm.nih.gov/pubmed/28834546 http://dx.doi.org/10.1002/jcph.974

Ejemplares similares

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
por: Hoover, Randall K., et al.
Publicado: (2018)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
por: Kurata, Akifumi, et al.
Publicado: (2019)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients
por: Kato, Jitsu, et al.
Publicado: (2019)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
por: Li, Yi, et al.
Publicado: (2023)

Early warning signal reliability varies with COVID-19 waves
por: O'Brien, Duncan A., et al.
Publicado: (2021)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Early Initiation of Colorectal Cancer Screening in Individuals with Affected First-degree Relatives
por: Murff, Harvey J., et al.
Publicado: (2007)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment
por: Torres, Rosarelis, et al.
Publicado: (2015)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g87r15g254p6nkjiqfs2eemg22